State Of The Industry: 2023 Predictions With Dr. Mark Sawicki

Cell and gene therapies hold the potential for accelerated growth this year. As many as 13 new cell or gene therapies could be approved in the US, Europe, or both by the end of 2023, expanding the number of patients who could be supported by these therapies. But amidst this growth, pain points concerning patient access to treatment centers and efficient supply chain logistics remain present. Inconsistent access to treatment centers across different geographies is leaving multiple companies unable to meet patient demand for these life-saving therapies.

As companies consider these obstacles in the ramp up of cell and gene therapies, Cryoport's upcoming leukapheresis supply chain platform aims to ease the burden on patients and offer standardized, integrated solutions to the Cell & Gene Therapy Market. Explore this evolving global market and how an optimized, end-to-end supply chain platform can ensure your company's success by offering life-saving therapies to more patients while ensuring the highest quality and safety standards.